Navigation Links
Pluristem to Present Two Scientific Posters at the International,Society for Cellular Therapy

NEW YORK--(BUSINESS WIRE)--May 2, 2007 - Pluristem Life Systems, Inc. (OTCBB:PLRS), a cell therapy Company dedicated to the commercialization of products for a variety of indications, announced today that it will present two scientific posters at the 13th Annual Meeting of the International Society for Cellular Therapy (ICST), June 24-27, 2007 in Sydney Australia.

Pluristem CEO and Chairman, Mr. Zami Aberman commented, "We are receiving more attention from the scientific community as our research and development team continues to successfully show how innovative our Placenta eXpanded (PLX) cells are. These PLX cells are mesenchymal stem cells expanded in our proprietary 3D PluriX(TM) Bioreactor System."

Pluristem's presentations are entitled, "Expansions of cord blood (CB) derived unseparated hematopoietic stem cells (HSC) co-cultured with mesenchymal cells growing in three dimensional (3-D) mode" and "Promotion of CD34+ cells engraftment using mesenchymal stromal cells expanded ex vivo in bioreactor containing high-density 3-D culture."

Pluristem will also attend the 2007 BIO International Convention being held at the Boston Convention & Exhibition Center from May 6-9, 2007. BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations.

Mr. Aberman added, "These venues provide us with several opportunities to interact with researchers, laboratory professional, physicians, regulatory specialists, business leaders, investments professionals and business colleagues, all working or interested in the cellular therapy sector."

About Pluristem

Pluristem Life Systems, Inc. is a Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of numerous severe degenerative, malignant and autoimmune disorders.
'"/>




Page: 1 2 3

Related medicine technology :

1. Pluristems PLX Cells Demonstrate Potential to Treat Parkinsons Disease
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
(Date:5/21/2013)... YORK , May 21, 2013 /PRNewswire/ ... research report is available in its catalogue: ... Markets and Technologies for Optical Coherence Tomography ...   STUDY OBJECTIVES ... this study is to offer synopsis of ...
(Date:5/21/2013)... and TARRYTOWN, N.Y. , May ... SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced ... published online the positive Phase 2a study results of ... is an investigational monoclonal antibody targeting the alpha subunit ... signaling of both IL-4 and IL-13, drivers of Th2 ...
(Date:5/21/2013)... MOUNTAIN VIEW, Calif. , May 21, 2013 /PRNewswire/ ... Brazil , Russia , ... (BRIC) are realizing there are no shortcuts.  This ... especially in the United States.  Companies must change the ... establishing value, customizing to local needs, and building regional ...
Breaking Medicine Technology:Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 2Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 3Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 4
... VIEW, Calif., Nov. 8, 2011 ChemoCentryx, Inc., today ... CCX354 at the Annual Meeting of the American College ... that specifically targets and inhibits the chemokine receptor known ... progression of rheumatoid arthritis (RA).  Results showed that CCX354 ...
... 8, 2011 Covance Inc. (NYSE: CVD ) ... Healthcare Conference on Thursday, November 10, 2011 at 3:00 p.m. ... at www.covance.com .  In order to register and download ... Covance, with headquarters in Princeton, New Jersey, is one ...
Cached Medicine Technology:ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 2ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 3ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 4Covance to Present at Credit Suisse 2011 Healthcare Conference 2
(Date:5/21/2013)... France: The Orsiro stent, which is a novel ... demonstrated non-inferiority to the Xience Prime everolimus-eluting stent ... lumen loss at nine months in the results ... today. , The BIOFLOW-II substudy used intravascular ultrasound ... assess neointimal hyperplasia and stent apposition at nine ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 The federal ... hip replacement lawsuits in U.S. District Court, ... response to a request from Plaintiffs’ Counsel to conduct ... The May 17th Order grants that request, and ... conducted. (In re: Wright Medical Technology, Inc., Conserve Hip ...
(Date:5/21/2013)... Focus, a non-profit organization striving to improve the living ... Corridor region, is releasing results for its 2013 Creative ... May 23rd at 10:30 a.m. The survey follows ... The survey is a critical component to the organizations’ ... and retain people of diverse backgrounds, cultures and beliefs ...
(Date:5/21/2013)... May 21, 2013 Modern couples ... help of Texas Counseling’s Sexuality and Relationship Workshops, ... the development of healthier habits for their relationship. ... for both couples and individuals at Texas Counseling. ... relationships and learn skills to develop long term ...
(Date:5/21/2013)... (May 21, 2013) Research into genetic features of ... of Colorado School of Medicine may lead to improved ... paper published online by JAMA . , The ... survival in some cases of pulmonary fibrosis, a chronic ... As a result of the study, researchers may want ...
Breaking Medicine News(10 mins):Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2
... ... Energy power system to supply all the loads in the new tower, including HVAC. ... as a practical matter, because east central Florida is hit frequently by hurricanes and thunderstorms ... ...
... , SAN PEDRO, Calif., Oct. 19 On ... the 11th annual surf cruise to Mexico will host their ... star line up of professional surfers, musicians, artists and movie ... The charity mission includes the W Hollywood Lions Club Global ...
... are already anticipating Halloween "trick or treating," some parents are ... to receive free candy. , Parents of children ... their child is the recipient of food outside the home. ... can stay safe without having to miss out on the ...
... (OTC Bulletin Board: OXBO) shareholders today voted to approve a ... general meeting in which shareholders also voted to approve all ... At the meeting, chairman and CEO Chris Stern also discussed ... Concentrate Gel for the skin care market and discussed an ...
... while blood flow is blocked protects tissue, animal study ... previous research, scientists have shown in animal studies that ... brain damage. , But it,s not a simple matter. ... depends on when 100 percent oxygen is given. ...
... no longer go after users or suppliers in states that ... News) -- The Obama administration has decided it will no ... the laws of states that allow use of the drug ... be sent in a Justice Department memo to federal prosecutors ...
Cached Medicine News:Health News:Florida's Halifax Health Relies on Standby Power System from MTU Onsite Energy for New 10-Story Emergency Facility 2Health News:Florida's Halifax Health Relies on Standby Power System from MTU Onsite Energy for New 10-Story Emergency Facility 3Health News:SURF CRUISE CUP 2009 2Health News:Halloween Doesn't Have to Be Scary for Kids With Food Allergies 2Health News:Oxygen Biotherapeutics, Inc. Shareholders Approve Reverse Stock Split 2Health News:Oxygen Biotherapeutics, Inc. Shareholders Approve Reverse Stock Split 3Health News:Timing of Oxygen After a Stroke May Matter 2Health News:U.S. Relaxes Opposition to Medical Marijuana 2Health News:U.S. Relaxes Opposition to Medical Marijuana 3
Inquire...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: